November 23, 2016 - By Louis Casey · 0 Comments
The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) registered an increase of 4.4% in short interest. ADMP’s total short interest was 1.98 million shares in November as published by FINRA. Its up 4.4% from 1.89 million shares, reported previously. With 214,200 shares average volume, it will take short sellers 9 days to cover their ADMP’s short positions. The short interest to Adamis Pharmaceuticals Corporation’s float is 13.17%. About 26,448 shares traded hands. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has declined 61.98% since April 21, 2016 and is downtrending. It has underperformed by 67.31% the S&P500.
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The company has a market cap of $63.14 million. The Firm is engaged in the development of its specialty pharmaceutical products. It currently has negative earnings. The Firm is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company .
Adamis Pharmaceuticals Corporation, incorporated on April 22, 2004, is a pharmaceutical company. The Firm is engaged in the development of its specialty pharmaceutical products. The Firm is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300.
More news for Adamis Pharmaceuticals Corp (NASDAQ:ADMP) were recently published by: Marketwatch.com, which released: “/quotes/zigman/3870025/realtime” on April 25, 2011. Quotes.Wsj.com‘s article titled: “DOW JONES, A NEWS CORP COMPANY” and published on May 16, 2012 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey